IOLCP IOL Chemicals and Pharmaceuticals Q4 FY26 results (Jan–Mar 2026) and concall
IOL Chemicals reported a strong Q4 and FY26, driven by record quarterly revenue, significant margin expansion, and robust growth in both pharmaceutical and chemical segments. The company's diversification strategy, capacity enhancements, and operational efficiencies contributed to improved profitability. Management expressed confidence in sustaining growth momentum and achieving mid-to-high teen revenue growth with improved EBITDA margins in FY27.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 17.2%, net profit up 65.6% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 526 | 523 | 528 | 552 | 568 +8% | 580 +11% | 619 +17% |
| EBITDA | 42 | 47 | 63 | 62 | 57 +36% | 57 +21% | 93 +48% |
| Net profit | 19 | 21 | 32 | 34 | 30 +58% | 21 +0% | 53 +66% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
